Search

everythinglearnresearchcommunity

for

Search:↓

How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.

The conversation discusses using 0.1% retinol as a potential substitute for 0.01% tretinoin with minoxidil for hair loss treatment. It mentions that tretinoin is not easily available in some countries, and retinol might be less effective but less harsh on the scalp.

The user is experiencing increased hair loss despite using finasteride and oral minoxidil and is hesitant to switch to dutasteride due to side effects and family planning concerns. Alternatives suggested include dutasteride, microneedling, and addressing stress or nutrient deficiencies.

The user has been using a hair loss treatment protocol including topical dutasteride, minoxidil with tretinoin, ketoconazole shampoo, microneedling, a laser cap, and vitamin D for 15 weeks, showing impressive progress. Feedback suggests continuing medical therapy for 12-24 months before considering a hair transplant.

The user started using dutasteride, biotin, vitamin D3, zinc, a multivitamin, and oral minoxidil, and noticed hair shedding after starting gym workouts. Another user suggested getting nutrients from food sources and mentioned that vitamin D3 might need supplementation if not obtained from sunlight.

A female with male-pattern hair loss (AGA) is seeking help after unsuccessful treatments with spironolactone and supplements, and is considering oral minoxidil and finasteride despite concerns about medication side effects. She has ruled out hormonal birth control and PRP/PRFM, and is looking into further medical advice due to abnormal lab results.

The conversation discusses a small patch of missing hair and whether treatments like Minoxidil, finasteride, or RU58841 could help. The user is seeking advice on addressing this specific hair issue.

The user switched from topical to oral minoxidil and started taking dutasteride, experiencing continuous shedding for over six months. They are concerned about the quality of the oral minoxidil and unsure if new vellus hair growth is related to the treatment.

A user shared a 14-month hair loss treatment update using dutasteride, minoxidil foam, a 1.5mm derma roller, and Nizoral, with noticeable hair regrowth and no side effects. The discussion highlights the effectiveness of microneedling in combination with topical treatments, with many users agreeing it significantly enhances results.

An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.

A user who had good results with finasteride and minoxidil for three years experienced sudden hair thinning and is switching to dutasteride combined with oral minoxidil and vitamin D3, and starting caffeine topicals. Some responses suggest the hair loss could be a synchronized shedding and advise patience, while others share their own positive experiences with dutasteride.

A user shared their 5-month hair regrowth progress using 0.5mg Dutasteride daily and 5% Minoxidil foam twice daily, reporting significant improvement despite initial shedding. Other users discussed their experiences with similar treatments, noting varied results and side effects, with some emphasizing the need for long-term commitment to maintain hair growth.

A 17-year-old with AGA is considering Revitacare Haircare Mesotherapy, which includes hyaluronic acid, amino acids, zinc, and B vitamins, injected into the scalp. One reply dismisses it as ineffective.

2-deoxy-d-ribose hair serum is now available in Australia, potentially aiding hair loss by promoting new blood vessel growth. Users are discussing its potential effectiveness compared to other treatments like Minoxidil, finasteride, and RU58841.

A user has been losing hair for two and a half years after a tropical trip and illness. A dermatologist prescribed betamethasone valerate 0.1% lotion, but the user is unsure if it's safe or effective for general hair loss.

The conversation discusses using 0.1% Alfatradiol compounded by a pharmacy for hair loss treatment. It also mentions Minoxidil, finasteride, and RU58841 as other treatments.

The user has been using 1 mg finasteride, topical minoxidil twice daily, 1 biotin vitamin, and a 0.5 mm dermaroller for hair loss treatment since April. They've seen progress but experienced a shedding event in October, and are hoping for increased density in the coming months.

Despite using finasteride, minoxidil, and RU58841, the user is experiencing slow hair loss, particularly at the hairline, and is considering additional treatments like microneedling and possibly switching to dutasteride. Concerns about medication side effects, such as reduced sperm count and performance anxiety, are also discussed.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

The user has been experiencing hair loss for over 5 years and is currently using a topical treatment of finasteride, minoxidil, and tretinoin, along with derma rolling and a hair growth oil. They have previously tried oral finasteride, pyrithione zinc, RU58841, and dutasteride, but are seeking advice on whether to retry dutasteride or find a more reliable source for RU58841 due to ongoing hair density loss.

A 24-year-old male experiencing diffused thinning discusses his DHT levels and hair density issues. He has not used finasteride or dutasteride and is considering AR inhibitors.

Dutasteride and oral minoxidil are not effectively stopping hair loss for the user, despite trying various treatments including ketoconazole shampoo. Suggestions include increasing dosages, considering alternative treatments, and consulting a doctor.

A user suspects vaping has contributed to their hair loss and plans to quit while using Minoxidil and finasteride. They are unsure if hair regrowth will be due to quitting vaping or the medications.

A 25-year-old noticed thinning hair at the temples and started using finasteride (1mg/day) for two months, along with keto shampoo twice a week and vitamins like vitamin D, biotin, and zinc. They are seeing some results and are hopeful about regaining lost hair.

Hair loss treatments like Dutasteride, RU58841, and Minoxidil may not work for everyone, as some individuals experience no improvement despite extensive use and research. Genetic factors can play a significant role, and standard treatments may not be effective for all.

The user is experiencing early hair thinning and is currently using finasteride and ketoconazole shampoo. They are considering adding minoxidil or switching to dutasteride for stronger DHT suppression, while also checking for iron deficiency.

Quitting smoking and vaping, along with taking spirulina, improved hair thickness for some users. Others noted that smoking, vaping, and drinking may contribute to hair thinning.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.